38 related articles for article (PubMed ID: 38663283)
1. Unique Binding Sites of Uricosuric Agent Dotinurad for Selective Inhibition of Renal Uric Acid Reabsorptive Transporter URAT1.
Fujita K; Isozumi N; Zhu Q; Matsubayashi M; Taniguchi T; Arakawa H; Shirasaka Y; Mori E; Tamai I
J Pharmacol Exp Ther; 2024 Jun; 390(1):99-107. PubMed ID: 38670801
[TBL] [Abstract][Full Text] [Related]
2. Xanthine Oxidoreductase in the Pathogenesis of Endothelial Dysfunction: An Update.
Mudgal R; Singh S
Curr Hypertens Rev; 2024; 20(1):10-22. PubMed ID: 38318826
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and evaluation of the in vitro activity of novel dual inhibitors of XOR and URAT1 containing a benzoic acid group.
Zhu XY; Chen HM; Zhang L; Qin YX; Li J
Chem Biol Drug Des; 2023 Dec; 102(6):1553-1567. PubMed ID: 37700463
[TBL] [Abstract][Full Text] [Related]
4. Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia.
Zheng F; Mai S; Cen X; Zhao P; Ye W; Ke J; Lin S; Hu H; Guo Z; Zhang S; Liao H; Wu T; Tian Y; Zhang Q; Pang J; Zhao Z
Bioorg Chem; 2024 Jun; 147():107381. PubMed ID: 38669781
[TBL] [Abstract][Full Text] [Related]
5. Renal Reabsorptive Transport of Uric Acid Precursor Xanthine by URAT1 and GLUT9.
Arakawa H; Amezawa N; Kawakatsu Y; Tamai I
Biol Pharm Bull; 2020; 43(11):1792-1798. PubMed ID: 33132325
[TBL] [Abstract][Full Text] [Related]
6. CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia.
Zhao ZA; Jiang Y; Chen YY; Wu T; Lan QS; Li YM; Li L; Yang Y; Lin CT; Cao Y; Zhou PZ; Guo JY; Tian YX; Pang JX
Acta Pharmacol Sin; 2022 Jan; 43(1):121-132. PubMed ID: 33767379
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia.
Zhao Z; Liu J; Kuang P; Luo J; Surineni G; Cen X; Wu T; Cao Y; Zhou P; Pang J; Zhang Q; Chen J
Eur J Med Chem; 2022 Feb; 229():114092. PubMed ID: 34998055
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of 3-phenyl substituted pyridine derivatives as potential dual inhibitors of XOR and URAT1.
Yang C; Cai H; Zhu X; Zhang L; Li J
Eur J Med Chem; 2024 May; 271():116407. PubMed ID: 38663283
[TBL] [Abstract][Full Text] [Related]
9. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout.
Hou Z; Ma A; Mao J; Song D; Zhao X
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):895-909. PubMed ID: 37994776
[TBL] [Abstract][Full Text] [Related]
10. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019).
Dong Y; Zhao T; Ai W; Zalloum WA; Kang D; Wu T; Liu X; Zhan P
Expert Opin Ther Pat; 2019 Nov; 29(11):871-879. PubMed ID: 31593642
[No Abstract] [Full Text] [Related]
11. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
12. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present).
Shi X; Zhao T; da Silva-Júnior EF; Zhang J; Xu S; Gao S; Liu X; Zhan P
Expert Opin Ther Pat; 2022 Dec; 32(12):1175-1184. PubMed ID: 36625031
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]